{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T22:32:57Z","timestamp":1764714777117},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100008741","name":"EULAR","doi-asserted-by":"crossref","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003748","name":"Swedish Society for Medical Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12891-016-1067-y","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T01:04:14Z","timestamp":1464915854000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Long-term outcomes of destructive seronegative (rheumatoid) arthritis \u2013 description of four clinical cases"],"prefix":"10.1186","volume":"17","author":[{"given":"Elena","family":"Nikiphorou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Sj\u00f6wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pekka","family":"Hannonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuomas","family":"Rannio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuulikki","family":"Sokka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,3]]},"reference":[{"issue":"69","key":"1067_CR1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"2010","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, et al. rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;2010(69):1580\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1067_CR2","doi-asserted-by":"crossref","first-page":"17372","DOI":"10.1073\/pnas.1114465108","volume":"108","author":"J Shi","year":"2011","unstructured":"Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A. 2011;108:17372\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1067_CR3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.38969","volume":"67","author":"GM Thiele","year":"2015","unstructured":"Thiele GM, Duryee MJ, Anderson DR, Klassen LW, Mohring SM, Young KA, et al. Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis. Arthritis Rheumatol. 2015;67:645\u201355.","journal-title":"Arthritis Rheumatol"},{"key":"1067_CR4","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205\u201319.","journal-title":"N Engl J Med"},{"key":"1067_CR5","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/art.11223","volume":"48","author":"S Rantapaa-Dahlqvist","year":"2003","unstructured":"Rantapaa-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741\u20139.","journal-title":"Arthritis Rheum"},{"key":"1067_CR6","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1002\/art.20553","volume":"50","author":"L Padyukov","year":"2004","unstructured":"Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 2004;50:3085\u201392.","journal-title":"Arthritis Rheum"},{"key":"1067_CR7","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.22525","volume":"56","author":"H Dongen van","year":"2007","unstructured":"van Dongen H, van Aken J, Lard LR, Ronday HK, Hulsmans HMJ, Speyer I, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56:1424\u201332.","journal-title":"Arthritis Rheum"},{"key":"1067_CR8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492\u2013509.","journal-title":"Ann Rheum Dis"},{"key":"1067_CR9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nrrheum.2014.194","volume":"11","author":"S Ajeganova","year":"2015","unstructured":"Ajeganova S, Huizinga TW. Rheumatoid arthritis: Seronegative and seropositive RA: alike but different? Nat Rev Rheumatol. 2015;11:8\u20139.","journal-title":"Nat Rev Rheumatol"},{"key":"1067_CR10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.berh.2014.10.016","volume":"28","author":"AG Pratt","year":"2014","unstructured":"Pratt AG, Isaacs JD. Seronegative rheumatoid arthritis: pathogenetic and therapeutic aspects. Best Pract Res Clin Rheumatol. 2014;28:651\u20139.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1067_CR11","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3899\/jrheum.140082","volume":"41","author":"L Barra","year":"2014","unstructured":"Barra L, Pope JE, Orav JE, Boire G, Haraoui B, Hitchon C, et al. Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J Rheumatol. 2014;41:2361\u20139.","journal-title":"J Rheumatol"},{"key":"1067_CR12","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1136\/ard.2009.109983","volume":"68","author":"T Sokka","year":"2009","unstructured":"Sokka T, Kautiainen H, Pincus T, Toloza S, da Rocha Castelar PG, Lazovskis J, et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis. 2009;68:1666\u201372.","journal-title":"Ann Rheum Dis"},{"key":"1067_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/03009748509104317","volume":"57","author":"K Kaarela","year":"1985","unstructured":"Kaarela K. Prognostic factors and diagnostic criteria in early rheumatoid arthritis. Scand J Rheumatol Suppl. 1985;57:1\u201354.","journal-title":"Scand J Rheumatol Suppl"},{"key":"1067_CR14","first-page":"527","volume":"17","author":"TM Sokka","year":"1999","unstructured":"Sokka TM, Kaarela K, M\u00f6tt\u00f6nen TT, Hannonen PJ. Conventional monotherapy compared to a \"sawtooth\" treatment strategy in the radiographic procession of rheumatoid arthritis over the first eight years. Clin Exp Rheumatol. 1999;17:527\u201332.","journal-title":"Clin Exp Rheumatol"},{"key":"1067_CR15","first-page":"1285","volume":"24","author":"K Kaarela","year":"1997","unstructured":"Kaarela K, Kautiainen H. Continuous progression of radiological destruction in seropositive rheumatoid arthritis. J Rheumatol. 1997;24:1285\u20137.","journal-title":"J Rheumatol"},{"key":"1067_CR16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s100670200096","volume":"21","author":"JK Jantti","year":"2002","unstructured":"Jantti JK, Kaarela K, Lehtinen KE. Seronegative oligoarthritis: a 23-year follow-up study. Clin Rheumatol. 2002;21:353\u20136.","journal-title":"Clin Rheumatol"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-016-1067-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T22:33:58Z","timestamp":1589668438000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-016-1067-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,3]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1186\/s12891-016-1067-y","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,3]]},"article-number":"246"}}